PMID- 19492656
OWN - NLM
STAT- MEDLINE
DCOM- 20090624
LR  - 20171116
IS  - 1081-1206 (Print)
IS  - 1081-1206 (Linking)
VI  - 102
IP  - 5
DP  - 2009 May
TI  - When is prophylaxis for hereditary angioedema necessary?
PG  - 366-72
LID - 10.1016/S1081-1206(10)60506-6 [doi]
AB  - OBJECTIVE: To determine when newer agents, such as C1 esterase inhibitor protein 
      (C1-INH), should be considered as prophylaxis to decrease hereditary angioedema 
      (HAE) attacks as an alternative to androgens, which have significant adverse 
      events. DATA SOURCES: A literature review (PubMed, Google, and Ovid), guideline 
      review, expert panel meeting, and group discussion were performed to decide when 
      prophylaxis is indicated. STUDY SELECTION: Articles addressing HAE therapy 
      published in the peer-reviewed literature were selected. RESULTS: The retrieved 
      studies demonstrate that C1-INH is effective and that the half-life makes it 
      attractive for prophylactic use. The short half-lives of ecallantide, icatibant, 
      and recombinant human C1-INH limit their use as prophylactic agents. Patients 
      with severe anxiety, more than 1 attack per month, rapid progression of attacks, 
      limited access to health care, more than 10 days lost from work or school per 
      year, previous laryngeal swelling, more than 3 emergency department visits per 
      year, more than 1 hospitalization per year, previous intubation, previous 
      intensive care unit care, significant compromise in quality of life, or narcotic 
      dependency should be considered for androgen or C1-INH prophylaxis therapy. 
      CONCLUSION: Patients with HAE with frequent attacks, severe attacks, past 
      laryngeal attacks, excessive loss of work or school, significant anxiety, and 
      poor quality of life should be considered for C1-INH prophylaxis, especially 
      those who fail, are intolerant of, have adverse reactions to, or are not 
      candidates for androgen therapy.
FAU - Craig, Timothy
AU  - Craig T
AD  - Department of Medicine and Pediatrics, Pennsylvania State University, College of 
      Medicine, Hershey, Pennsylvania 17033, USA. tcraig@psu.edu
FAU - Riedl, Marc
AU  - Riedl M
FAU - Dykewicz, Mark S
AU  - Dykewicz MS
FAU - Gower, Richard G
AU  - Gower RG
FAU - Baker, James
AU  - Baker J
FAU - Edelman, Frank J
AU  - Edelman FJ
FAU - Hurewitz, David
AU  - Hurewitz D
FAU - Jacobs, Joshua
AU  - Jacobs J
FAU - Kalfus, Ira
AU  - Kalfus I
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - 0 (Androgens)
RN  - 0 (Bradykinin Receptor Antagonists)
RN  - 0 (Complement C1 Inactivator Proteins)
RN  - 0 (Complement C1 Inhibitor Protein)
RN  - 0 (Peptides)
RN  - 0 (SERPING1 protein, human)
RN  - 5Q6TZN2HNM (ecallantide)
RN  - 7PG89G35Q7 (icatibant)
RN  - EC 3.4.21.- (Kallikreins)
RN  - S8TIM42R2W (Bradykinin)
SB  - IM
MH  - Androgens/adverse effects/therapeutic use
MH  - Angioedemas, Hereditary/diagnosis/epidemiology/*prevention & control
MH  - Bradykinin/adverse effects/analogs & derivatives/therapeutic use
MH  - Bradykinin Receptor Antagonists
MH  - Clinical Trials as Topic
MH  - Complement C1 Inactivator Proteins/adverse effects/genetics/therapeutic use
MH  - Complement C1 Inhibitor Protein
MH  - Humans
MH  - Kallikreins/antagonists & inhibitors
MH  - Mortality
MH  - Peptides/adverse effects/therapeutic use
RF  - 28
EDAT- 2009/06/06 09:00
MHDA- 2009/06/25 09:00
CRDT- 2009/06/05 09:00
PHST- 2009/06/05 09:00 [entrez]
PHST- 2009/06/06 09:00 [pubmed]
PHST- 2009/06/25 09:00 [medline]
AID - S1081-1206(10)60506-6 [pii]
AID - 10.1016/S1081-1206(10)60506-6 [doi]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 2009 May;102(5):366-72. doi: 
      10.1016/S1081-1206(10)60506-6.